A drug prescribed for heart rhythm disorders, prolonged-release flecanaide is experiencing supply tensions worldwide. In order not to leave patients without a solution, the Medicines Agency has established replacement recommendations.
Who are flecainide medicines intended for?
Sustained-release flecainide medicines, used to improve symptoms of heart rhythm disorders. Concretely, this antiarrhythmic modifies the transmission of nerve impulses to the heart muscle and fights against anarchic contractions. It is also used in patients who have an implantable cardiac defibrillator to reduce electric shocks.
Why are these drugs in short supply?
These drugs are currently in short supply worldwide. Problems that the laboratories explain by difficulties in the supply of raw materials and packaging items. According to the ANSM, “A date for a return to normal supplies cannot yet be brought forward, although supplies are regularly made..
So that the patients concerned can at least receive appropriate treatment, the ANSM has drawn up recommendations for pharmacists and prescribing doctors, in consultation with the French Society of Cardiology and its rhythmology and cardiac stimulation group, the unions and representatives of pharmacists. , the College of General Medicine and patient associations, including the association of wearers of cardiac electrical devices (Apodec).
The objective is to facilitate the implementation of a replacement treatment adapted to each situation, either directly via the pharmacist, or following medical advice, if another molecule must be used as a replacement.
What are the different alternatives?
The pharmacist must inform the patient when a replacement is necessary and advise him to see his doctor in the event of the occurrence of an adverse effect or symptom that he deems unusual. He also writes the name of the medicine delivered on the prescription and informs the prescriber of this replacement.
Sustained Release Flecainide Supply Tensions
—ANSM (@ansm) September 1, 2023
Several solutions are considered depending on the availability of treatments:
If supplies are sufficient, replacement with another specialty flecainide sustained-release (PR), or immediate, should be preferred. For example: a 150 mg LP capsule can be replaced by a 50 mg LP capsule and a 100 mg LP capsule, to be taken once a day;
If prolonged-release forms are not available, the pharmacist may replace them with an immediate-release specialty, respecting the same prescribed daily dose, and indicating to the patient that the dose must be divided into 2 doses per day ( morning and evening). For example: 1 100 mg tablet to be taken morning and evening, instead of 1 200 mg LP capsule once a day.
2nd intention solution
If the replacement prolonged-release (LP) or immediate-release specialties are out of stock, extemporaneous preparations of an immediate-release form of flecainide can be produced with a raw material for pharmaceutical use. For example: Flecaine LP 150 mg 1 capsule per day = masterful preparation of Flecainide acetate 75mg 1 capsule in the morning and 1 capsule in the evening.
Last solution requiring a consultation with a cardiologist
As a last resort, flecainide can be replaced by a drug based on propafenone, after consultation with a cardiologist and on presentation of a prescription. This consultation is necessary in order to control the patient’s heart rate, due to the bradycardic properties of propafenone (slowing of the heart rate). In addition, this substitution requires close monitoring, in particular by electrocardiogram on D8/D10, in order to check the patient’s heart rate. The dosage must be defined by the doctor on a case-by-case basis.
In summary, patients should know that:
If your treatment is unavailable, your pharmacist can give you another equivalent medicine.
- Consult your doctor if:
- your pharmacist has not been able to provide you with an equivalent treatment, so that your doctor can adapt your treatment;
- unusual symptoms appear when your treatment is changed.